|Day's Range||269.09 - 275.51|
|52 Week Range||236.67 - 333.65|
|PE Ratio (TTM)||17.20|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In 2016, Biogen’s (BIIB) Tysabri reported revenues of around $2.0 billion, which is ~4% growth year-over-year (or YoY).
In 2016, Biogen’s (BIIB) Tecfidera reported revenues of ~$4.0 billion, which reflected ~9% growth year-over-year (or YoY).
Currently, Biogen is conducting 13 clinical studies in early phases and expects promising results from those trials.